CRISPR-Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer.
收藏数据链接：
官方服务：
资源简介：
Datasets associated with CRISPR-Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer. Boumelha, J., de Castro, A., Bah, N., Cha, H., de Carné Trécesson, S., Rana, S., ... & Downward, J. (2024). CRISPR–Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer. <i>Cancer research</i>, <i>84</i>(14), 2231-2246.
创建时间：
2026-01-02
